ID
42247
Beschreibung
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872
Link
https://clinicaltrials.gov/ct2/show/NCT00391872
Stichworte
Versionen (3)
- 28-11-15 28-11-15 -
- 14-04-21 14-04-21 - Ahmed Rafee, MD
- 15-04-21 15-04-21 - Ahmed Rafee, MD
Rechteinhaber
AstraZeneca
Hochgeladen am
15 april 2021
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Excerpt PLATO Acute coronary Syndrome NCT00391872
Section Investigational Products
Ähnliche Modelle
Section Investigational Products
C1608718 (UMLS CUI [1,2])
C1608718 (UMLS CUI [1,2])
C0070166 (UMLS CUI [1,2])
C0070166 (UMLS CUI [1,2])
Keine Kommentare